Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy

S Ma, MA Caligiuri, J Yu - Trends in immunology, 2022 - cell.com
Natural killer (NK) cells, a crucial component of the innate immune system, have long been
of clinical interest for their antitumor properties. Almost every aspect of NK cell immunity is …

Emerging principles of cytokine pharmacology and therapeutics

RA Saxton, CR Glassman, KC Garcia - Nature Reviews Drug Discovery, 2023 - nature.com
Cytokines are secreted signalling proteins that play essential roles in the initiation,
maintenance and resolution of immune responses. Although the unique ability of cytokines …

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni… - Nature, 2022 - nature.com
Expansion and differentiation of antigen-experienced PD-1+ TCF-1+ stem-like CD8+ T cells
into effector cells is critical for the success of immunotherapies based on PD-1 blockade …

[HTML][HTML] Engineering interferons and interleukins for cancer immunotherapy

PG Holder, SA Lim, CS Huang, P Sharma… - Advanced drug delivery …, 2022 - Elsevier
Cytokines are a class of potent immunoregulatory proteins that are secreted in response to
various stimuli and act locally to regulate many aspects of human physiology and disease …

The present and future of bispecific antibodies for cancer therapy

C Klein, U Brinkmann, JM Reichert… - Nature Reviews Drug …, 2024 - nature.com
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Recent advances and next breakthrough in immunotherapy for cancer treatment

L Yang, Q Ning, S Tang - Journal of immunology research, 2022 - Wiley Online Library
With the huge therapeutic potential, cancer immunotherapy is expected to become the
mainstream of cancer treatment. In the current field of cancer immunotherapy, there are …

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy

V Niederlova, O Tsyklauri, M Kovar, O Stepanek - Trends in immunology, 2023 - cell.com
The therapeutic potential of interleukin (IL)-2 in cancer treatment has been known for
decades, yet its widespread adoption in clinical practice remains limited. Recently, chimeric …

Research progress of interleukin-15 in cancer immunotherapy

M Cai, X Huang, X Huang, D Ju, YZ Zhu… - Frontiers in …, 2023 - frontiersin.org
Interleukin-15 (IL-15) is a cytokine that belongs to the interleukin-2 (IL-2) family and is
essential for the development, proliferation, and activation of immune cells, including natural …

Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells

G Zhou, R Lieshout, GS van Tienderen… - British journal of …, 2022 - nature.com
Background Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to
improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI …

MultiNicheNet: a flexible framework for differential cell-cell communication analysis from multi-sample multi-condition single-cell transcriptomics data

R Browaeys, J Gilis, C Sang-Aram, P De Bleser… - BioRxiv, 2023 - biorxiv.org
Dysregulated cell-cell communication is a hallmark of many disease phenotypes. Due to
recent advances in single-cell transcriptomics and computational approaches, it is now …